Monograph
N03AG04 - Vigabatrin |
Propably not porphyrinogenic |
PNP |
Rationale
Most of the drug remains unmetabolized. No evidence of CYP-inducing effects. Warned against on grounds of high incidence of severe visual impairment.
Chemical description
Fatty acid derivative, soluble in water. Used together with other drugs in therapy resistent epilepsy. Irreversible visual field defects takes place with an incidence of 10-20%, limiting the usefulness of the drug. About 60-80 % is eliminated in unchanged form in urine within 24 hours. Vigabatrin does not induce CYPs. EPI-list: safe South African list: use with care French list: avoid, known to have precipitated an acute attack See Hahn et al. Effects of new antikonvulsant medications on porphyrin synthesis in cultured liver cells…Neurology 1997; 49: 97-106. See also Bylesjo. Lakartidningen 1996.
IPNet drug reports
Uneventful use reported in 1 patient with acute porphyria.
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Netherlands
Belgium
United Kingdom
Denmark
Norway
Poland
Luxembourg
Iceland
Finland
Latvia© NAPOS 2024